85-6044-27 [取扱停止]SARS-CoV-2 Spike Glycoprotein (S2), Recombinant, aa1000-1200, His-Tag 100ug 544709

※お見積書はカートで印刷できます

冷凍

特徴

  • SARS-CoV-2 is a respiratory virus which causes coronavirus disease 2019 (COVID-19); it spreads primarily through contact with an infected person through respiratory droplets generated when a person coughs or sneezes, or through droplets of saliva or discharge from the nose. The incubation period is believed to range from 2-11 days. Infection with SARS-CoV-2 can cause mild symptoms including a runny nose, sore throat, cough, and fever. However, it can be more severe for some people and can lead to pneumonia or breathing difficulties. The elderly, and people with pre-existing medical conditions (such as, diabetes and heart disease) appear to be more vulnerable to becoming severely ill with the virus. There are currently more than 40,000 confirmed cases from 24 countries, although the vast majority are still within China, with more than 900 deaths to date (WHO, 2020).
  • The coronavirus spike (S) glycoprotein is a class I viral fusion protein on the outer envelope of the virion that plays a critical role in viral infection by recognizing host cell receptors and mediating fusion of the viral and cellular membranes (Li, 2016). The S glycoprotein is synthesized as a precursor protein consisting of ~1300aa that is then cleaved into an amino N-terminal S1 subunit (~700aa) and a C-terminal S2 subunit (~600aa). Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD), while the S2 subunit contains a hydrophobic fusion peptide and two heptad repeat regions. Triggered by receptor binding, proteolytic processing and/or acidic pH in the cellular compartments, the class I viral fusion protein undergoes a transition from a metastable prefusion state to a stable postfusion state during infection, in which the receptor-binding subunit is cleaved, and the fusion subunit undergoes large-scale conformational rearrangements to expose the hydrophobic fusion peptide, induce the formation of a six-helix bundle, and bring the viral and cellular membranes close for fusion (Belouzard et al., 2012). The trimeric SARS coronavirus (SARS-CoV) S glycoprotein consisting of three S1-S2 heterodimers binds the cellular receptor angiotensin-converting enzyme 2 (ACE2) and mediates fusion of the viral and cellular membranes through a pre- to postfusion conformation transition (Song et al., 2018).
  • Recombinant protein corresponding to aa1000-1200 from SARS-CoV-2 Spike Glycoprotein (S2), strain Wuhan-Hu-1, fused to 6xHis-Tag at N-terminal, expressed in E.coli.
  • Moleculer Weight:~23kD
  • Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

仕様

  • Size:100ug
  • Source Antigen:Recombinant, E. coli
  • Grade:Purified
  • Purity:≥90%
  • Form:Supplied as a liquid in PBS. No preservative added.
  • Molecular Weight Non Ab:23
  • この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
  • 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
  • 【試薬に関するお問合せ】
  • アズワン株式会社 試薬・プロセス材料グループ
  • TEL:06-6447-8641
  • FAX:06-6447-8642
  • E-mail:[email protected]
アズワン品番
85-6044-27
型番
544709
入り数
1個
標準価格
234,000円(税抜)
WEB価格
取扱停止
アズワン在庫 [?]
数量

※お気に入り機能はログイン後にご利用いただけます

よくあるご質問

よくあるご質問(FAQ)

掲載カタログ情報

掲載カタログ名 掲載ページ

次の商品を登録しました。

商品計:

お買い物を続ける カートを見る